Adoptive cell transfer: a clinical path to effective cancer immunotherapy (original) (raw)

• Rosenberg, S. A. et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N. Engl. J. Med. 319, 1676–1680 (1988). The first paper to demonstrate the regression of cancer using TIL for the immunotherapy of patients with metastatic melanoma.
  Article CAS Google Scholar
• Dudley, M. E. et al. Cancer regression and autoimmunity in patients following clonal repopulation with anti-tumor lymphocytes. Science 298, 850–854 (2002).
  Article CAS Google Scholar
• Dudley, M. E. et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 2346–2357 (2005). References 2 and 3 demonstrate that lymphodepletion prior to ACT can lead to increased cancer regression as well as clonal repopulation of patients with anti-tumour lymphocytes.
  Article CAS Google Scholar
• Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126–129 (2006). The first paper demonstrating the adoptive cell transfer of lymphocytes transduced with a retrovirus encoding TCRs that recognize a cancer antigen can mediate anti-tumour responses in patients with metastatic melanoma.
  Article CAS Google Scholar
• Rosenberg, S. A. et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485–1492 (1985).
  Article CAS Google Scholar
• Rosenberg, S. A., Yang, J. C., White, D. E. & Steinberg, S. M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2. Ann. Surg. 228, 307–319 (1998).
  Article CAS Google Scholar
• Lotze, M. T. et al. High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses, treatment related morbidity and histologic findings. J. Am. Med. Assoc. 256, 3117–3124 (1986).
  Article CAS Google Scholar
• Kammula, U. S., White, D. E. & Rosenberg, S. A. Trends in the safety high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 83, 797–805 (1998).
  Article CAS Google Scholar
• Phan, G. Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372–8377 (2003).
  Article CAS Google Scholar
• Attia, P. et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23, 6043–6053 (2005).
  Article CAS Google Scholar
• Van der Bruggen, P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643–1647 (1991).
  Article CAS Google Scholar
• Rosenberg, S. A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10, 281–287 (1999).
  Article CAS Google Scholar
• Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nature Med. 10, 909–915 (2004).
  Article CAS Google Scholar
• Rosenberg, S. A. et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J. Immunol. 175, 6169–6176 (2005). The demonstration that peptide vaccines are capable of generating large numbers of anti-tumour lymphocytes in vivo , but these lymphocytes do not appear to have any in vivo ability to prevent recurrence.
  Article CAS Google Scholar
• Mitchison, N. A. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J. Exp. Med. 102, 157–177 (1955). A seminal paper demonstrating the role of the cellular immune response in the rejection of tumour transplants.
  Article CAS Google Scholar
• Delorme, E. J. & Alexander, P. Treatment of primary fibrosarcoma in the rat with immune lymphocytes. Lancet 2, 117–120 (1964).
  Article CAS Google Scholar
• Fefer, A. Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice. Cancer Res. 29, 2177–2183 (1969).
  CAS PubMed Google Scholar
• Cheever, M. A., Kempf, R. A. & Fefer, A. Tumor neutralization, immunotherapy, and chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro. J. Immunol. 119, 714–718 (1977).
  CAS PubMed Google Scholar
• Eberlein, T. J., Rosenstein, M. & Rosenberg, S. A. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in IL-2. J. Exp. Med. 156, 385–397 (1982). Demonstration that the intravenous administration of anti-tumour lymphocytes expanded in IL2 could mediate the regression of established disseminated syngeneic tumours in mice.
  Article CAS Google Scholar
• Donohue, J. H. et al. The systemic administration of purified interleukin-2 enhances the ability of sensitized murine lymphocyte to cure a disseminated syngeneic lymphoma. J. Immunol. 132, 2123–2128 (1984).
  CAS PubMed Google Scholar
• Rosenberg, S. A., Spiess, P. & Lafreniere, R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318–1321 (1986). The first demonstration in murine models that the adoptive transfer of TIL could mediate the regression of established murine tumours.
  Article CAS Google Scholar
• Overwijk, W. W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569–580 (2003). This paper demonstrated that adoptive cell transfer, vaccine and IL2 administration could mediate the rejection of large established transgenic B16 melanomas in mice.
  Article CAS Google Scholar
• Antony, P. A. et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174, 2591–2601 (2005).
  Article CAS Google Scholar
• Gattinoni, L. et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202, 907–912 (2005).
  Article CAS Google Scholar
• Wrzesiniski, C. et al. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J. Clin. Invest. 117, 492–501 (2007).
  Article Google Scholar
• Gattinoni, L. et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115, 1616–1626 (2005).
  Article CAS Google Scholar
• Paulos, C. M. et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J. Clin. Invest. 117, 2197–2204 (2007).
  Article CAS Google Scholar
• Abad, J. D. et al. T-cell receptor gene therapy of established tumors in a murine melanoma model. J. Immunother. 31, 1–6 (2008).
  Article CAS Google Scholar
• Muul, L. M., Spiess, P. J., Director, E. P. & Rosenberg, S. A. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 138, 989–995 (1987). The first description of the ability of TIL in the human to recognize human tumour antigens presented on cancer cells.
  CAS PubMed Google Scholar
• Dudley, M. E., Wunderlich, J. R., Shelton, T. E., Even, J. & Rosenberg, S. A. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26, 332–342 (2003).
  Article Google Scholar
• Rosenberg, S. A. et al. Treatment of patients with metastatic melanoma using autologous tumor-infiltrating lymphocytes and interleukin-2. J. Natl Cancer Inst. 86, 1159–1166 (1994).
  Article CAS Google Scholar
• Aebersold, P. et al. Lysis of autologous melanoma cells by tumor infiltrating lymphocytes: association with clinical response. J. Natl Cancer Inst. 13, 932–937 (1991).
  Article Google Scholar
• Schwartzentruber, D. J. et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor infiltrating lymphocytes and interleukin-2. J. Clin. Oncol. 12, 1475–1483 (1994).
  Article CAS Google Scholar
• Rosenberg, S. A. et al. Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323, 570–578 (1990).
  Article CAS Google Scholar
• Dummer, W. et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 110, 185–192 (2002).
  Article CAS Google Scholar
• Yee, C. et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl Acad. Sci. USA 99, 16168–16173 (2002).
  Article CAS Google Scholar
• Robbins, P. F. et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173, 7125–7130 (2004). This paper demonstrated that persistence of adoptively transferred cells correlated directly with the likelihood of cancer regression.
  Article CAS Google Scholar
• Zhou, J., Shen, X., Hodes, R. J., Rosenberg, S. A. & Robbins, P. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175, 7046–7052 (2005). The paper shows that the telomere length of the transferred lymphocytes correlated both with in vivo persistence of the transferred cells as well as with tumour regression.
  Article CAS Google Scholar
• Powell, D. J., Dudley, M. E., Robbins, P. F. & Rosenberg, S. A. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 101, 241–250 (2004).
  Google Scholar
• Ochsenbein, A. F. et al. CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. J. Exp. Med. 200, 1407–1417 (2004).
  Article CAS Google Scholar
• Marijt, W. A. E. et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1 or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc. Natl Acad. Sci. USA 100, 2742–2747 (2003).
  Article CAS Google Scholar
• Kolb, H. J. et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76, 2462–2465 (1990). This paper was the first to show that treatment with donor lymphocytes could mediate cytogenetic remissions in patients with chronic myeloid leukaemia.
  CAS PubMed Google Scholar
• Mackinnon, S. et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86, 1261–1268 (1995).
  CAS PubMed Google Scholar
• Riddell, S. R., Bleakley, M., Nishida, T., Berger, C. & Warren, E. H. Adoptive transfer of allogeneic antigen-specific T cells. Biol. Blood Marrow Transplant. 12, 9–12 (2006).
  Article CAS Google Scholar
• Papadopoulos, E. B. et al. Infusions of donor leukocytes to treat Epstein–Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330, 1185–1191 (1994). This paper showed that the infusion of normal donor lymphocytes could achieve complete responses in patients with lymphomas that occurred following the treatment of leukaemia with chemotherapy and T-cell-depleted allogeneic stem cell grafts.
  Article CAS Google Scholar
• Rooney, C. M. et al. Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr-virus-related lymphoproliferation. Lancet 345, 9–13 (1995).
  Article CAS Google Scholar
• Rooney, C. M. et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92, 1549–1555 (1998). References 46 and 47 showed that tumour regression could be obtained by the infusion of long-term cultured EBV-specific T-cell lines.
  CAS PubMed Google Scholar
• Khanna, R. et al. Activation and adoptive transfer of Epstein–Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc. Natl Acad. Sci. USA 96, 10391–10396 (1999).
  Article CAS Google Scholar
• Haque, T. et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein–Barr virus-specific cytotoxic T cells. Transplantation 72, 1399–1402 (2001).
  Article CAS Google Scholar
• Haque, T. et al. Allogeneic cytotoxic T cell therapy for EBV-positive post transplant lymphoproliferative disease: results of a phase 2 multicentre clinical trial. Blood 110, 1123–1131 (2007).
  Article CAS Google Scholar
• Straathof, K. et al. Treatment of nasopharyngeal carcinoma with Epstein–Barr virus-specific T lymphocytes. Blood 105, 1898–1904 (2005).
  Article CAS Google Scholar
• Comoli, P. et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein–Barr virus-targeted cytotoxic T lymphocytes. J. Clin. Oncol. 23, 8942–8949 (2005).
  Article CAS Google Scholar
• Bollard, C. et al. Cytotoxic T lymphocyte therapy for Epstein–Barr virus Hodgkin's disease. J. Exp. Med. 200, 1623–1633 (2004).
  Article CAS Google Scholar
• Riddell, S. R. et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257, 238–241 (1992).
  Article CAS Google Scholar
• Sadelain, M., Riviere, I. & Brentjens, R. Targeting tumours with genetically enhanced T lymphocytes. Nature Rev. Cancer 3, 35–45 (2003).
  Article CAS Google Scholar
• Murphy, A. et al. Gene modification strategies to induce tumor immunity. Immunity 22, 403–414 (2005).
  Article CAS Google Scholar
• Cole, D. J. et al. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res. 55, 748–752 (1995).
  CAS PubMed Google Scholar
• Hughes, M. S. et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum. Gene. Ther. 16, 457–472 (2005).
  Article CAS Google Scholar
• Morgan, R. A. et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J. Immunol. 171, 3287–3295 (2003).
  Article CAS Google Scholar
• Zhao, Y. et al. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J. Immunol. 174, 4415–4423 (2005).
  Article CAS Google Scholar
• Cohen, C. J., Zhao, Y., Zheng, Z., Rosenberg, S. A. & Morgan, R. A. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66, 8878–8886 (2006).
  Article CAS Google Scholar
• Cohen, C. J. et al. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67, 3898–3903 (2007).
  Article CAS Google Scholar
• Theobald, M. B. J., Dittmer, D., Levine, A. J. & Sherman, L. A. Targeting p53 as a general tumor antigen. Proc. Natl Acad. Sci. USA 92, 11993–11997 (1995).
  Article CAS Google Scholar
• Kuball, J., Schmitz, F. W. & Voss, R. H. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 22, 117–129 (2005).
  Article CAS Google Scholar
• Cohen, C. J. et al. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J. Immunol. 175, 5799–5808 (2005). References 58–65 demonstrate that TCRs can be identified that recognize cancer antigens and that transduction of these TCRs into normal human cells can transfer this antigen recognition.
  Article CAS Google Scholar
• Li, Y. et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nature Biotech. 23, 349–354 (2005).
  Article CAS Google Scholar
• Gross, G., Waks, T. & Eshhar, Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl Acad. Sci. USA 86, 10024–10028 (1989).
  Article CAS Google Scholar
• Kershaw, M. H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106–6115 (2006).
  Article CAS Google Scholar
• Lamers, C. H. J. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20–e22 (2006).
  Article Google Scholar
• Park, J. R. et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 15, 825–833 (2007).
  Article CAS Google Scholar
• Brentjens R. J. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nature Med. 9, 279–286 (2003).
  Article CAS Google Scholar
• Johnson, L. A. et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating. J. Immunol. 177, 6548–6559 (2006).
  Article CAS Google Scholar
• Fernandez-Cruz, E., Woda, B. A. & Feldman, J. D. Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes. J. Exp. Med. 152, 823–841 (1980).
  Article CAS Google Scholar
• Berendt, M. J. & North, R. J. T-cell-mediated suppression of anti-tumor immunity: an explanation for progressive growth of an immunogenic tumor. J. Exp. Med. 151, 69–80 (1980).
  Article CAS Google Scholar
• Mule, J. J., Shu, S., Schwarz, S. L. & Rosenberg, S. A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225, 1487–1489 (1984).
  Article CAS Google Scholar
• Liu, K. & Rosenberg, S. A. Transduction of an interleukin-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J. Immunol. 167, 6356–6365 (2001).
  Article CAS Google Scholar
• Waldmann, T. A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nature Rev. Immunol. 6, 595–601 (2007).
  Article Google Scholar
• Ruggeri, L., Mancusi, A., Capanni, M., Martelli, M. F. & Velardi, A. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr. Opin. Immunol. 17, 211–217 (2005).
  Article CAS Google Scholar
• Dudley, M. E. et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. (in the press).